Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health.
- Journal Article
- Research Support
- N.I.H.
- Extramural
- Research Support
- Non-U.S. Gov't
Summary
The research presents the development and evaluation of a vaccine to prevent Hendra virus (HeV), a disease transmitted from bats to horses and then to humans, showcasing a One Health approach that considers human, animal, and environmental health.
Introduction
The recent emergence of multiple highly pathogenic zoonotic diseases (diseases transmitted from animals to humans) has highlighted the importance of the interconnectedness between human, animal, and environmental health. This concept, known as One Health, has been showcased in the research by the development of a vaccine for Hendra virus, a zoonotic paramyxovirus that primarily affects horses but can also infect humans.
- Hendra virus was first discovered in 1994 and since then, periodic outbreaks have occurred, affecting both horses and the humans closely associated with them.
- One proposed solution for these outbreaks was the eradication of bat populations, which are the main carriers of the virus. However, bats play a crucial role in the ecosystem, particularly in pollination and controlling insect populations, making this solution undesirable.
Development and Evaluation of the Vaccine
The aim of the study was to develop and evaluate a vaccine for horses to prevent Hendra virus transmission and thus protect horses, humans, and the environmental health.
- The researchers have elucidated the development of this vaccine in detail, describing the various stages of testing and confirming the efficacy.
- As horses are the primary ‘intermediate hosts’ for HeV before it infects humans, vaccinating them effectively breaks the chain of transmission.
Consequences and Significance
The One Health approach in the development of the HeV vaccine provides a valuable model for managing other zoonotic diseases.
- This approach would not only curb the health risks associated with HeV for horses and humans, but also lead to the preservation of bat populations, thereby saving the environmental health.
- The research emphasizes that controlling the disease in the primary host (here, horses) is often more feasible and sustainable than targeting the original carriers (bats), which often have important ecological roles.
- This study is a key example of how the one health approach can be used to manage and prevent diseases at the interface of humans, animals, and the environment
Cite This Article
Publication
Researcher Affiliations
MeSH Terms
- Animals
- Antibodies, Viral / blood
- Antibodies, Viral / immunology
- Environmental Health
- Female
- Ferrets
- Guinea Pigs
- Hendra Virus / genetics
- Hendra Virus / immunology
- Henipavirus Infections / prevention & control
- Horse Diseases / pathology
- Horse Diseases / prevention & control
- Horse Diseases / virology
- Horses
- Humans
- Immunization
- Neutralization Tests
- Viral Vaccines / immunology
- Zoonoses / pathology
- Zoonoses / prevention & control
- Zoonoses / virology
Grant Funding
- R01 AI054715 / NIAID NIH HHS
- U01 AI077995 / NIAID NIH HHS
- AI077995 / NIAID NIH HHS
- AI054715 / NIAID NIH HHS
References
- Halpin K, Hyatt AD, Fogarty R, Middleton D, Bingham J, Epstein JH, Rahman SA, Hughes T, Smith C, Field HE, Daszak P. Pteropid bats are confirmed as the reservoir hosts of henipaviruses: a comprehensive experimental study of virus transmission.. Am J Trop Med Hyg 2011 Nov;85(5):946-51.
- Playford EG, McCall B, Smith G, Slinko V, Allen G, Smith I, Moore F, Taylor C, Kung YH, Field H. Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008.. Emerg Infect Dis 2010 Feb;16(2):219-23.
- Field H, Crameri G, Kung NY, Wang LF. Ecological aspects of hendra virus.. Curr Top Microbiol Immunol 2012;359:11-23.
- Williamson MM, Hooper PT, Selleck PW, Gleeson LJ, Daniels PW, Westbury HA, Murray PK. Transmission studies of Hendra virus (equine morbillivirus) in fruit bats, horses and cats.. Aust Vet J 1998 Dec;76(12):813-8.
- Weingartl HM, Berhane Y, Czub M. Animal models of henipavirus infection: a review.. Vet J 2009 Sep;181(3):211-20.
- Marsh GA, Haining J, Hancock TJ, Robinson R, Foord AJ, Barr JA, Riddell S, Heine HG, White JR, Crameri G, Field HE, Wang LF, Middleton D. Experimental infection of horses with Hendra virus/Australia/horse/2008/Redlands.. Emerg Infect Dis 2011 Dec;17(12):2232-8.
- Middleton DJ, Weingartl HM. Henipaviruses in their natural animal hosts.. Curr Top Microbiol Immunol 2012;359:105-21.
- Degeling C, Kerridge I. Hendra in the news: public policy meets public morality in times of zoonotic uncertainty.. Soc Sci Med 2013 Apr;82:156-63.
- Mendez DH, Judd J, Speare R. Unexpected result of Hendra virus outbreaks for veterinarians, Queensland, Australia.. Emerg Infect Dis 2012 Jan;18(1):83-5.
- Mahalingam S, Herrero LJ, Playford EG, Spann K, Herring B, Rolph MS, Middleton D, McCall B, Field H, Wang LF. Hendra virus: an emerging paramyxovirus in Australia.. Lancet Infect Dis 2012 Oct;12(10):799-807.
- Jones KE, Patel NG, Levy MA, Storeygard A, Balk D, Gittleman JL, Daszak P. Global trends in emerging infectious diseases.. Nature 2008 Feb 21;451(7181):990-3.
- Mazet JA, Clifford DL, Coppolillo PB, Deolalikar AB, Erickson JD, Kazwala RR. A "one health" approach to address emerging zoonoses: the HALI project in Tanzania.. PLoS Med 2009 Dec;6(12):e1000190.
- Abraham G, Muschialli J, Middleton D. Animal experimentation in level 4 facilities. In: Richmond JY, editor. Anthology of biosafety: BSL-4 laboratories. Mundelein (IL): American Biological Safety Association; 2002. p. 343–59.
- Bossart KN, Crameri G, Dimitrov AS, Mungall BA, Feng YR, Patch JR, Choudhary A, Wang LF, Eaton BT, Broder CC. Receptor binding, fusion inhibition, and induction of cross-reactive neutralizing antibodies by a soluble G glycoprotein of Hendra virus.. J Virol 2005 Jun;79(11):6690-702.
- Pallister J, Middleton D, Wang LF, Klein R, Haining J, Robinson R, Yamada M, White J, Payne J, Feng YR, Chan YP, Broder CC. A recombinant Hendra virus G glycoprotein-based subunit vaccine protects ferrets from lethal Hendra virus challenge.. Vaccine 2011 Aug 5;29(34):5623-30.
- Mungall BA, Middleton D, Crameri G, Bingham J, Halpin K, Russell G, Green D, McEachern J, Pritchard LI, Eaton BT, Wang LF, Bossart KN, Broder CC. Feline model of acute nipah virus infection and protection with a soluble glycoprotein-based subunit vaccine.. J Virol 2006 Dec;80(24):12293-302.
- McEachern JA, Bingham J, Crameri G, Green DJ, Hancock TJ, Middleton D, Feng YR, Broder CC, Wang LF, Bossart KN. A recombinant subunit vaccine formulation protects against lethal Nipah virus challenge in cats.. Vaccine 2008 Jul 23;26(31):3842-52.
- Bossart KN, Rockx B, Feldmann F, Brining D, Scott D, LaCasse R, Geisbert JB, Feng YR, Chan YP, Hickey AC, Broder CC, Feldmann H, Geisbert TW. A Hendra virus G glycoprotein subunit vaccine protects African green monkeys from Nipah virus challenge.. Sci Transl Med 2012 Aug 8;4(146):146ra107.
- Steffen DL, Xu K, Nikolov DB, Broder CC. Henipavirus mediated membrane fusion, virus entry and targeted therapeutics.. Viruses 2012 Feb;4(2):280-308.
- Broder C, Geisbert T, Xu K, Nikolov D, Wang L-F, Middleton D. Immunization strategies against henipaviruses. In: Lee B, Rota PA, editors. Henipavirus. Berlin: Springer; 2012. p. 197–223.
- Bossart KN, Zhu Z, Middleton D, Klippel J, Crameri G, Bingham J, McEachern JA, Green D, Hancock TJ, Chan YP, Hickey AC, Dimitrov DS, Wang LF, Broder CC. A neutralizing human monoclonal antibody protects against lethal disease in a new ferret model of acute nipah virus infection.. PLoS Pathog 2009 Oct;5(10):e1000642.
- Bossart KN, Geisbert TW, Feldmann H, Zhu Z, Feldmann F, Geisbert JB, Yan L, Feng YR, Brining D, Scott D, Wang Y, Dimitrov AS, Callison J, Chan YP, Hickey AC, Dimitrov DS, Broder CC, Rockx B. A neutralizing human monoclonal antibody protects african green monkeys from hendra virus challenge.. Sci Transl Med 2011 Oct 19;3(105):105ra103.
- Guillaume V, Contamin H, Loth P, Georges-Courbot MC, Lefeuvre A, Marianneau P, Chua KB, Lam SK, Buckland R, Deubel V, Wild TF. Nipah virus: vaccination and passive protection studies in a hamster model.. J Virol 2004 Jan;78(2):834-40.
- Guillaume V, Contamin H, Loth P, Grosjean I, Courbot MC, Deubel V, Buckland R, Wild TF. Antibody prophylaxis and therapy against Nipah virus infection in hamsters.. J Virol 2006 Feb;80(4):1972-8.
- Guillaume V, Wong KT, Looi RY, Georges-Courbot MC, Barrot L, Buckland R, Wild TF, Horvat B. Acute Hendra virus infection: Analysis of the pathogenesis and passive antibody protection in the hamster model.. Virology 2009 May 10;387(2):459-65.
- Graham BS, Crowe JE. Immunization against viral diseases. In: Knipe DM, Griffin DE, Lamb RA, Straus SE, Howley PM, Martin MA, et al., editors. Fields virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007. p. 487–538.
- Wolinsky JS, Waxham MN, Server AC. Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.. J Virol 1985 Mar;53(3):727-34.
- Plotkin SA. Vaccination against the major infectious diseases.. C R Acad Sci III 1999 Nov;322(11):943-51.
- Snoy PJ. Establishing efficacy of human products using animals: the US food and drug administration's "animal rule".. Vet Pathol 2010 Sep;47(5):774-8.
- Breed AC, Yu M, Barr JA, Crameri G, Thalmann CM, Wang LF. Prevalence of henipavirus and rubulavirus antibodies in pteropid bats, Papua New Guinea.. Emerg Infect Dis 2010 Dec;16(12):1997-9.
- Drexler JF, Corman VM, Gloza-Rausch F, Seebens A, Annan A, Ipsen A, Kruppa T, Müller MA, Kalko EK, Adu-Sarkodie Y, Oppong S, Drosten C. Henipavirus RNA in African bats.. PLoS One 2009 Jul 28;4(7):e6367.
- Epstein JH, Prakash V, Smith CS, Daszak P, McLaughlin AB, Meehan G, Field HE, Cunningham AA. Henipavirus infection in fruit bats (Pteropus giganteus), India.. Emerg Infect Dis 2008 Aug;14(8):1309-11.